Trial reportSchizophrenia bulletin2015
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
Trial report in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.The Cochrane database of systematic reviews · 2021 · on this mapPooled it
- Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Pooled it
- Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial.BMC psychiatry · 2025Trial
- Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial.The international journal of neuropsychopharmacology · 2022Trial
- Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology · 2021Trial
- Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response.Brain imaging and behavior · 2019Trial
- A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.Schizophrenia research · 2019Trial
- Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.The international journal of neuropsychopharmacology · 2018Trial
- Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Psychopharmacology · 2017Trial
- Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.Schizophrenia bulletin · 2015Trial
- The Relationship between Baseline Neutrophils Counts and Response to 12 Weeks of Antipsychotics in First-Episode Psychosis.Research square · 2026Article
- Pharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy.Biomedicines · 2025Review
- Cerebellar-Cortical Connectivity and Prediction of Antipsychotic Treatment Response in First-Episode Psychosis.Schizophrenia bulletin · 2025Article
- Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis.Pharmacy (Basel, Switzerland) · 2023Review
- Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Article
- Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses.Frontiers in psychiatry · 2022Article
- Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms.Human psychopharmacology · 2021Article
- Pharmacotherapy treatment of stimulant use disorder.The mental health clinician · 2021Article
- Long acting aripiprazole influences cognitive functions in recent onset schizophrenia.Psychopharmacology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 9 institutions in 2 countries.
Funding
Abstract
Research findings are particularly important for medication choice for first-episode patients as individual prior medication response to guide treatment decisions is unavailable. We describe the first large-scale double-masked randomized comparison with first-episode patients of aripiprazole and risperidone, 2 commonly used first-episode treatment agents. One hundred ninety-eight participants aged 15-40 years with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder Not Otherwise Specified, and who had been treated in their lifetime with antipsychotics for 2 weeks or less were randomly assigned to double-masked aripiprazole (5-30 mg/d) or risperidone (1-6 mg/d) and followed for 12 weeks. Positive symptom response rates did not differ (62.8% vs 56.8%) nor did time to response. Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia. Body mass index change did not differ between treatments but advantages were found for aripiprazole treatment for total and low-density lipoprotein cholesterol, fasting glucose, and prolactin levels. Post hoc analyses suggested advantages for aripiprazole on depressed mood. Overall, if the potential for akathisia is a concern, low-dose risperidone as used in this trial maybe a preferred choice over aripiprazole. Otherwise, aripiprazole would be the preferred choice over risperidone in most situations based upon metabolic outcome advantages and some symptom advantages within the context of similar positive symptom response between medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.